Dogwood Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Dogwood Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($15.74M) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($3.81M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($3.81M) | Nov 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($10.92M) | Nov 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($10.92M) | May 9, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($10.92M) | Aug 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.28M) | Nov 7, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($1.05M) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($1.05M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($1.29M) | May 9, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($1.29M) | Aug 13, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($1.29M) | Nov 7, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($1.24M) | Nov 8, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($1.44M) | Aug 9, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($1.44M) | Nov 8, 2024 |
| Q1 | 2023 | Jun 30, 2023 | ($1.44M) | Aug 11, 2023 |
| Q2 | 2024 | Mar 31, 2023 | ($1.52M) | Aug 9, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($1.52M) | Nov 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($1.52M) | May 10, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($2.58M) | Nov 13, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($15.81M) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($3.92M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($4.43M) | May 9, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.30M) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($1.07M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($1.31M) | May 9, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($1.27M) | Nov 8, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($1.48M) | Aug 9, 2024 |
| Q1 | 2023 | Jun 30, 2023 | ($1.48M) | Aug 11, 2023 |
| Q1 | 2024 | Mar 31, 2023 | ($1.56M) | May 10, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($2.59M) | Nov 13, 2023 |
| Q1 | 2023 | Jun 30, 2022 | ($3.67M) | Aug 11, 2023 |
| Q2 | 2022 | Jun 30, 2022 | ($3.67M) | Aug 12, 2022 |
| Q1 | 2023 | Mar 31, 2022 | ($3.96M) | May 12, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($4.11M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($4.28M) | Aug 12, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($3.06M) | May 13, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($2.66M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($538.4K) | Aug 13, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($382.6K) | May 14, 2021 |